Nachrichten zur ASTRAZENECA DL-,25 SP.ADR Aktie

AstraZeneca trumps Q2 forecasts, keeps outlook amid pricing, trade pressures…

AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney disease drugs, but…

29 July 2025 AstraZeneca results: H1 and Q2 2025 Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date Revenue and…

FTSE 100 dips negative Lloyds Bank and BT Group among fallers Rolls-Royce and AstraZeneca in positive ground US-EU deal better…

In the most recent trading session, Astrazeneca (AZN) closed at $72.66, indicating a -1.38% shift from the previous trading day.…

It’s the most money the company has ever invested in a single manufacturing site.…

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump administration claiming some…

AstraZeneca is investing heavily in US facilities to counteract tariff impacts, planning substantial growth through local manufacturing by 2030…

AstraZeneca PLC (LSE:AZN) has announced plans to invest $50 billion in the United States by 2030, marking the pharmaceutical giant’s…

AstraZeneca announces $50 billion US investment in manufacturing and R&D…

AstraZeneca pledges $50 bln investment in US as pharma tariffs loom…

AstraZeneca announced that it will invest $50 billion in the U.S. by 2030, including a multi-billion-dollar manufacturing site in Virginia.…

Der schwedisch-britische Pharmakonzern AstraZeneca kündigt Milliarden-Investitionen in den USA an – und macht dabei kein Geheimnis daraus, dass Zeitpunkt und…

…

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on…

AstraZeneca announces largest ever investment in U.S. manufacturing…

Astrazeneca (AZN) closed the most recent trading day at $69.26, moving 1.17% from the previous trading session.…

AZNs anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.…

AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study…

AstraZeneca on Wednesday said that its experimental drug anselamimab did not meet the main goal of a late-stage study for…

ZÜRICH (dpa-AFX Analyser) - Die schweizerische Großbank UBS hat Astrazeneca auf "Buy" mit einem Kursziel von 14200 Pence belassen. In…

LONDON (dpa-AFX Broker) - Positive Studiendaten zu einem Medikament von Astrazeneca sind am Montag an der Londoner Börse gut…

Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) were both down over 1% on Friday, but the shares are worth buying, analysts…

AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.…

Der britische Pharmakonzern spreche derzeit mit Summit Therapeutics über eine Vereinbarung, in deren Rahmen AstraZeneca über mehrere Jahre bis zu…

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported on Thursday,…

NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Astrazeneca von 14524 auf 14806 Pence angehoben…

Suggestions that AstraZeneca might cross the Atlantic should act as a huge wake-up call.…

AstraZeneca is the most valuable company listed on London’s FTSE 100 index.…

London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca…

Astrazeneca (AZN) reached $71.46 at the closing of the latest trading day, reflecting a +2.26% change compared to its last…

Trading in AstraZenecas (NASDAQ: AZN) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to…

Report claims CEO Pascal Soriot talked in private about moving UK’s most valuable listed company and considered shifting its domicile…

Pharma giant’s chief discusses shifting listing to US in potential blow to UK capital…

AstraZeneca reports total voting rights at over 1.55 billion shares…

AstraZeneca chief executive Pascal Soriot is considering moving the companys stock market listing to the United States, The Times reported…

Sir Pascal Soriot is frustrated with restrictions on medicines by Nice and pricing under an NHS rebate scheme…

…

For investors in the United States, its pretty easy to get overexposed to domestic stocks. These are the brands that…

Attraktive Investmentperspektive: AstraZeneca zeigt Interesse an KI-Onkologie-Konsortium "PROmAI"^EQS-Media / 28.06.2025 / 14:56 CET/CESTOnco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco…

Whats the biggest misconception about investing? The idea that you need a lot of money to get started is certainly…

Onco-Innovations begrüßt das Interesse von AstraZeneca an einer Gründungsrolle in PROmAI, einem von Inka angeführten KI-Onkologie-Konsortium^Emittent / Herausgeber: MCS Market…

Vancouver, Kanada - 27. Juni 2025 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" oder…

IRW-PRESS: Onco-Innovations Limited: Onco-Innovations begrüßt das Interesse von AstraZeneca an einer Gründungsrolle in PROmAI, einem von Inka angeführten KI-Onkologie-KonsortiumVancouver, Kanada…

The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street…